ArriVent BioPharma, Inc.
No SEC Form 4 filings for $AVBP in the last 30 days.
See all $AVBP insider activity →ArriVent BioPharma's average price target was reduced by analysts from $42.45 to $37.55, with a range of $18 to $50. This suggests a 32% upside from the Oct. 5 closing price. All 12 analysts maintain a 'Buy' rating.
ArriVent BioPharma's lung cancer drug failed to meet its primary trial endpoint, causing shares to drop 49.07% to $14.49, a 52-week low. The decline was reported by Benzinga Pro.
ArriVent BioPharma's lung cancer drug, furmonertinib, failed to meet its main goal in a late-stage study, missing a key benchmark in tumor progression. The company's shares fell over 50% in pre-market trading. CEO Bing Yao stated the company will review the data to determine next steps. The drug is approved in China for certain lung cancers, but the study's failure may limit its market potential.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning AVBP (ArriVent BioPharma, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 5 bearish.
Recent AVBP coverage spans financial news, market movers and earnings.
ArriVent BioPharma's average price target was reduced by analysts from $42.45 to $37.55, with a range of $18 to $50. This suggests a 32% upside from the Oct. 5 closing price. All 12 analysts maintain a 'Buy' rating.
ArriVent BioPharma's lung cancer drug failed to meet its primary trial endpoint, causing shares to drop 49.07% to $14.49, a 52-week low. The decline was reported by Benzinga Pro.
ArriVent BioPharma's lung cancer drug, furmonertinib, failed to meet its main goal in a late-stage study, missing a key benchmark in tumor progression. The company's shares fell over 50% in pre-market trading. CEO Bing Yao stated the company will review the data to determine next steps. The drug is approved in China for certain lung cancers, but the study's failure may limit its market potential.
The trial miss is material negative news for AVBP.
Missed primary endpoint likely pressures AVBP stock.
AlphAI scores every news story that mentions AVBP with an AI model for sentiment and relevance, and aggregates insider trades from ArriVent BioPharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ArriVent BioPharma's average price target was reduced by analysts from $42.45 to $37.55, with a range of $18 to $50. This suggests a 32% upside from the Oct. 5 closing price. All 12 analysts maintain a 'Buy' rating.
1 min readArriVent BioPharma's lung cancer drug failed to meet its primary trial endpoint, causing shares to drop 49.07% to $14.49, a 52-week low. The decline was reported by Benzinga Pro.
1 min readArriVent BioPharma's lung cancer drug, furmonertinib, failed to meet its main goal in a late-stage study, missing a key benchmark in tumor progression. The company's shares fell over 50% in pre-market trading. CEO Bing Yao stated the company will review the data to determine next steps. The drug is approved in China for certain lung cancers, but the study's failure may limit its market potential.
2 min readArriVent BioPharma's (AVBP) stock dropped 63% after its Phase 3 FURVENT trial for firmonertinib failed to meet the primary endpoint of progression-free survival in NSCLC patients. The trial compared two doses of firmonertinib against chemotherapy, with neither dose achieving statistical significance. Secondary endpoints showed some clinical benefit, but the company expressed disappointment in the results. The trial enrolled 398 patients globally.
2 min readArriVent's Phase 3 FURVENT trial of firmonertinib missed the primary PFS endpoint by BICR (p=0.0654). The 240mg arm showed median PFS of 11.0 months vs. 9.5 months for control. Investigator-assessed PFS favored 240mg (11.1 vs. 7.1 months). Confirmed ORR by BICR was 60% for 240mg, 35% for 160mg, and 33% for control. Safety data were consistent with prior studies.
2 min readArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC NEWTOWN SQUARE, PA, October 6, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage
2 min readArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2026 Financial Results · Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 · ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to
7 min readClear Street names five biotech stocks for 2H 2026 catalysts: MoonLake (MLTX) Buy, $70 target; Cullinan (CGEM) Buy, $46; Zura Bio (ZURA) Buy, $18; Arrivent (AVBP) Buy, $47; Protagonist (PTGX) Buy, $116. It cites planned clinical readouts and regulatory milestones, plus MLTX’s ~$200M offering and AVBP’s up to $250M ATM filing.
7 min readArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001868279 0001868279 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readArriVent BioPharma (NASDAQ:AVBP) shares rose 9.7% mid-day Thursday, trading up to $33.00 and last at $32.68 versus a prior close of $29.78. Mid-day volume was 194,230 shares, down 61% from the average. Analysts cited include B. Riley, Truist, HC Wainwright, Oppenheimer, and others; consensus is “Moderate Buy” with an average $43.38 target. The company reported May 11 EPS of -$0.96, missing estimates of -$0.88.
4 min read
